TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back
STOCKS

Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back

PRESS RELEASES

PTC Therapeutics To Host Call To Review Results From Its Study Of Translarna™ (ataluren) In Patients With Nonsense Mutation Duchenne Muscular Dystrophy

PRESS RELEASES

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

PTC Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference

PRESS RELEASES

PTC Announces Translarna™ Approval In Russia For The Treatment Of Duchenne Muscular Dystrophy

PRESS RELEASES

PTC Therapeutics Announces Initiation Of Global Phase 3 Clinical Trial To Evaluate Vatiquinone In Friedreich Ataxia

PRESS RELEASES

PTC Therapeutics Announces Key Regulatory Designations For PTC596 To Advance Treatment Of Two Rare Oncology Indications

PRESS RELEASES

PTC Therapeutics Announces That PTC518 Has Entered Into A Phase 1 Clinical Trial For The Huntington's Disease Program

PRESS RELEASES

PTC Therapeutics Announces Initiation Of A Registration-Directed Clinical Trial To Evaluate Vatiquinone In Mitochondrial Epilepsy

PRESS RELEASES

PTC Therapeutics And AADC Family Network Announce First-Ever AADC Deficiency Awareness Day In Massachusetts

PRESS RELEASES

Evrysdi™ (risdiplam) Continues To Make Global Progress For The Treatment Of Spinal Muscular Atrophy

PRESS RELEASES

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program For Individuals Suspected Of Having Neurotransmitter Disorders

PRESS RELEASES

PTC Therapeutics' 2020 STRIVE Awards For Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations

PRESS RELEASES

PTC Therapeutics To Present At The Cantor Virtual Global Healthcare Conference

PRESS RELEASES

PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval Of Evrysdi™ (risdiplam)

PRESS RELEASES

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

PTC Announces The Acceptance Of The European Marketing Authorization Application For Evrysdi™ (risdiplam) For The Treatment Of Spinal Muscular Atrophy

PRESS RELEASES

PTC Therapeutics Announces FDA Approval Of Evrysdi™ (risdiplam) For The Treatment Of Spinal Muscular Atrophy In Adults And Children 2 Months And Older

PRESS RELEASES

PTC Therapeutics' Mary Frances Harmon Named One Of The Most Inspiring Leaders In Life Sciences By PharmaVOICE Magazine

PRESS RELEASES

PTC Therapeutics To Host Deep Dive Webinar On Splicing Platform

PRESS RELEASES

PTC Therapeutics Announces Agreement To Monetize A Portion Of The Risdiplam Royalty Stream For $650 Million

PRESS RELEASES

PTC Therapeutics Announces First Patient Dosed In Phase 1 Trial For PTC857

PRESS RELEASES

PTC Therapeutics Announces CHMP Recommendation Of Translarna™ (ataluren) Label Update For Non-Ambulatory Patients With Duchenne Muscular Dystrophy

PRESS RELEASES

PTC Therapeutics Announces The Initiation Of A Phase 2/3 Clinical Trial To Evaluate PTC299 For The Treatment Of COVID-19